IMMU

[fous]

Immunomedics, Inc.. The Group's principal activity is to develop, manufacture and market monoclonal antibody-based products for the detection and treatment of cancer, autoimmune and other serious diseases. The Group has developed a number of advanced technologies to create humanized antibodies that can be either alone in unlabeled form, or conjugated with radioactive isotopes, chemotherapeutics or toxins to create highly targeted agents. The Group's product candidates and technologies are protected by a portfolio of intellectual property that includes 90 issued patents in the United States and 250 other issued patents worldwide. The Group currently markets CEA-Scan and Leukoscan in the United States, Canada, the European Union and Australia.

Shares Out:    54.07M        
Market Cap:    140.05M        
52wk High: 1/24/2005    4.00        
52wk Low: 10/19/2005    1.63        
Avg Volume:    276,900  

Recently rebounding from its 52 wk low, IMMU looks to be forming a new bullish trend back by volume and good news.

Technically price action has recently broken out of a short term trading range as well as broke out of a longer term descending wedge on heavy volume and news yesterday.

Their preclinical trials for there drugs seem to be going well and its had a positive effect on the pps

Immunomedics Reports Preclinical Results on New Therapeutic
- Properties of New Immunotoxin Described in Blood Article -
12/15/2005 8:30:49 AM

   MORRIS PLAINS, N.J., Dec 15, 2005 /PRNewswire-FirstCall via COMTEX/ -- Immunomedics, Inc. (IMMU) today announced that the results of preclinical studies of its new antibody fusion protein, CD74-RNase immunotoxin, appeared in today's issue of Blood, the official journal of the American Society of Hematology (ASH), and were also presented orally at the annual meeting of ASH on December 12, 2005, by Company Chairman, Dr. David M. Goldenberg.

This is the first recombinant immunotoxin comprising a humanized antibody against CD74 and an engineered ribonuclease (RNase). CD74 is a molecule present on certain blood cells involved in immune responses, as well as on lymphomas, myelomas, and some solid tumors. The recombinant immunotoxin is manufactured using the mammalian cell culture platform used to produce the Company's other therapeutic humanized antibodies.

"Cell culture and animal studies indicated that this new immunotoxin killed CD74-positive human lymphoma and myeloma cells by interfering with RNA and protein synthesis. It was therapeutic in mice bearing human lymphomas, where a single dose as low as 1 microgram per mouse was effective, but a higher dose of 5-15 micrograms had even greater curative effects when given as a single dose in early or late stage disease," commented Dr. Goldenberg. "Some toxicity was encountered at doses of 50 micrograms and higher, but this was 10-50-times the dose needed for cure," he added. "Thus, we are encouraged with the therapeutic index of this new molecule," Dr. Goldenberg stated.

Cynthia L. Sullivan, President and Chief Executive Officer, remarked: "Our humanized anti-CD74 antibody has shown therapeutic activity in lymphoma and myeloma transplants as a naked (unconjugated) antibody, conjugated with doxorubicin, and now as a fusion protein with RNase, thus providing us with several product candidates for further evaluation."

The reference for the article is: Chang et al., Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005; 106:4308-14.

...

Immunomedics Reports Humanized Anti-CD20 Antibody Appears Safe and Active in Non-Hodgkin's Lymphoma
- Initial Clinical Results Presented at the 47th Annual Meeting of American Society of Hematology (ASH) -
12/12/2005 8:30:59 AM

   ATLANTA, Dec 12, 2005 /PRNewswire-FirstCall via COMTEX/ -- Immunomedics, Inc. (IMMU), a leading biopharmaceutical company focused on developing monoclonal antibodies, today reported initial response and safety results with the Company's humanized anti-CD20 (hA20) monoclonal antibody in patients with non-Hodgkin's lymphoma (NHL) at the 47th Annual Meeting of ASH. The results were presented by Franck Morschhauser, MD, Centre Hospitalier Regional Universitaire de Lille, Lille, France, lead investigator of the open-label, multi-center, Phase I/II, dose-escalation study.

Thirty-four adult patients with documented CD20-positive B-cell NHL were enrolled and were infused once weekly for four weeks consecutively with 120, 200, 375, or 750 mg/m(2) of hA20. Treatment responses from twenty-three assessable patients with at least one post-treatment evaluation were reported at the meeting. The overall objective response rate was 61% (14/23) with 26% (6/23) of patients having a complete response (CR/CRu). Moreover, complete responses were observed at all dose levels, including 43% (3/7) patients receiving 120 mg/m(2) of hA20, with 28% (2/7) having a partial response. Median infusion times for 375 mg/m(2) of hA20 were 3.3 hours for the first infusion, 2.0 hours for subsequent infusions. At lower initial doses of 120 and 200 mg/m(2) of hA20, infusion times of 2 hours for the first and 1 hour for subsequent infusions were reported.

"We are very encouraged by these preliminary results and are particularly enthused by the high proportion of complete responses in patients who received 120 mg/m2 of hA20, the lowest dose used in the trial. More importantly, a complete response rate of 43% (3/7) was observed in a small group of patients who had 2-4 prior treatments with rituximab," remarked Cynthia L. Sullivan, President and Chief Executive Officer. "We are in the process of formulating the optimal dose to bring the study to the next phase," Ms. Sullivan added.

Thirty-three patients received all four infusions with one rituximab- sensitive patient discontinuing treatment after developing allergic reactions at first infusion. Other than mild to moderate transient infusion reactions, predominantly with the first infusion, no significant toxicity was reported. No immunogenicity was seen in twenty-four patients tested at least once. As expected, peripheral blood B-cell depletion occurred after the first infusion and persisted for samples obtained up to 12 weeks following fourth infusion, with analysis ongoing. Pharmacokinetic results after first and fourth infusions demonstrate a mean antibody serum half-life of 5.3 plus or minus 5.3 and 12.0 plus or minus 8.7 days, respectively.

...

Immunomedics Reports Updated Clinical Results of Epratuzmab-Rituximab Combination in Lymphoma
- Abstract Published at American Society of Hematology (ASH) 47th Annual Meeting -
12/9/2005 8:30:32 AM

   ATLANTA, Dec 09, 2005 /PRNewswire-FirstCall via COMTEX/ -- Immunomedics, Inc. (IMMU), a leading biopharmaceutical company focused on developing monoclonal antibodies, announced today results of a trial conducted at eight centers in Europe testing the safety and response rates of its lead product, epratuzumab, in combination with rituximab in the treatment of patients with non-Hodgkin's lymphoma (NHL).

The multi-center trial enrolled a total of thirty two patients with follicular or indolent NHL who received four consecutive weekly infusions of 360 mg/m2 of epratuzumab followed by the same weekly schedule of 375 mg/m2 rituximab. Prior to joining this study, sixteen patients had received two or more chemotherapy regimens and eleven patients had rituximab therapy. Twenty patients, or 62%, achieved an objective response, including 25% with complete responses (CR/CRu) and 37% with partial responses. The median response duration was 16.5 months and the median time-to-progression was 11 months.

Further analysis using the Follicular Lymphoma International Prognostic Index (FLIPI), a new prognostic index specifically designed for follicular lymphoma patients, revealed that those patients having the lowest prognostic index scores, or best prognosis, had the best outcome. Specifically, at FLIPI scores of 0-1, there was an 82% (9/11) objective response rate and a complete response rate of 36% (4/11), with a median duration of response of 15.7 months and a median time-to-progression of 19.2 months.

"These results are encouraging regarding the potential of combination therapy involving CD22 and CD20 monoclonal antibodies in the treatment of patients with NHL, and confirm earlier results from a single-center trial at the NY Hospital-Cornell Medical Center where patients with good prognostic indices were studied," commented Cynthia L. Sullivan, President and Chief Executive Officer. "It appears that both antibodies have different mechanisms of action. We anticipate that the complete trial results, including patients with aggressive NHL, toxicity data, and longer follow-up, will be published in 2006," she commented further.

In addition to the two pivotal Phase III ALLEVIATE trials in patients with lupus, epratuzumab is currently being studied in patients with Waldenstrom's Macroglobulinemia, a rare, chronic type of lymphoma, and by the Children's Oncology Group (COG) of the National Cancer Institute (NCI) in children with acute lymphoblastic leukemia. The North Central Cancer Treatment Group, a national clinical research group sponsored by the NCI, also plans to evaluate epratuzumab in combination with rituximab and CHOP chemotherapy in aggressive NHL patients.

...

-fousc[/size][/color]

[fous]

Buying IMMU tomorrow.

Hold as long as it closes above the ascending trendline.

-fousc

[fous]

In at the open of 2.80

[Terliso]

little bit late...but also IN @ 2.92 let see what this baby brings

[Terliso]

I'm still IN @ 2.92...RED now but I'll hold this BABY

[Terliso]

IMMU up 6%
Today a White Closing Marubozu was formed. This shows that the day opened and then prices went lower slightly, however it was followed by a rally that drove the prices over the opening price and the rally continued all day ending with a closing price equal to the high of the day

[Terliso]

i'm out from 2.92 to 3.45..... 18.15% GAIN

[Terliso]

Buying back IMMU... touched the 13 day EMA

[Holygrale]

Here is a good buying opportunity. Analyst mid December set a $8.00 12 month target.

[la-onda]

Setravis,
please MERGE THE IMMU threads

Upgrade from Lazard price target 6$

[calven]

What is going on with IMMU - why the runup?

ANyone like it here?

[ScottishTrader]

wow!!!  like the chart!!!

Symmetric/ascending triangle setup looks ready to go.  A break of $5 would put a target of $6.29 IN PLAY.  Yesterday's volum also suggests IMMU is gettign ready to go here....

not sure what is driving it, but when the cart talks, its pays to listen!!

[setravis]

AP
Immunomedics' Cancer Therapy Gets Patent
Tuesday October 16, 10:40 am ET 
Immunomedics' Pancreatic Cancer Therapy Gets U.S. Patent, Shares Rise Sharply


MORRIS PLAINS, N.J. (AP) -- Immunomedics Inc. said Tuesday the biopharmaceutical company received a patent for its product candidate hPAM4 to treat pancreatic cancer, sending its stock sharply higher.


Shares of Immunomedics rose 44 cents, or 17.6 percent, to $3.01 in morning trading on more-than-double average volume.

Humanized PAM4, or hPAM4, is characterized as a monoclonal antibody.

Monoclonal antibodies are the most widely used form of cancer immunotherapy, a treatment that uses certain parts of the immune system to fight cancer, according to the American Cancer Society.

The product candidate is designed to target an epitope, or marker, in the so-called MUC1 antigen expressed in most pancreatic cancer. Antigens refer to any substance that causes the body to produce natural antibodies.

Morris Plains, N.J.-based Immunomedics said the patent for hPAM4 covers its use in the diagnosis and therapy of pancreatic cancers.

The National Cancer Institute estimates there will be 37,170 new pancreatic cancer cases in the United States in 2007.

[setravis]

Press Release Source: Immunomedics, Inc.


Immunomedics Awarded U.S. Patent for Humanized PAM4 Monoclonal Antibody and Its Use in the Diagnosis and Therapy of Pancreatic Cancer
Tuesday October 16, 8:30 am ET


MORRIS PLAINS, N.J., Oct. 16, 2007 (PRIME NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM:IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced it has received notice that its patent application for ``Monoclonal antibody hPAM4'' will issue as U.S. patent no. 7,282,567 today. The patent covers the composition of matter for the MUC1-antigen binding humanized antibody and its use in the diagnosis and therapy of pancreatic cancers.


``We are delighted to receive this patent award. hPAM4 is an important product candidate in our clinical pipeline. In light of the potentially-favorable risk-reward profile of this antibody for the therapy of pancreatic cancer, and assuming clinical trials will support marketing approval, we will consider developing this product through commercialization on our own,'' commented Cynthia L. Sullivan, Company President and CEO.

Initial clinical results from a Phase I dose-escalation study with hPAM4 labeled with the radioisotope, yttrium-90 (Y-90), in patients with unresectable and metastatic pancreatic cancer were encouraging and the study has completed patient enrollment. A second dose-escalation study using smaller Y-90 doses given repeatedly to patients and in combination with gemcitabine is planned for early 2008.

About hPAM4

hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancer, but not pancreatitis, normal pancreas or most other normal tissues. Preclinical studies with PAM4 labeled with the radioisotope, Yttrium-90, demonstrated favorable tumor responses, which could be further improved when given in combination with gemcitabine. The Phase I dose-escalation study in pancreatic cancer patients has also produced encouraging initial results, as presented at the Annual Meeting of the Society of Nuclear Medicine in June, 2007. Future plans include a fractionated dose-escalation study in which smaller Y-90 doses are given to patients repeatedly, in combination with gemcitabine.

About Pancreatic Cancer

According to the National Cancer Institute, pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2007, an estimated 37,000 Americans will be diagnosed with the disease, and about 33,000 patients will die from it. For patients with advanced cancers, the overall 5-year survival rate of all stages is less than 1%. For those patients with small and localized disease that can be completely resected surgically, 5-year survival rates improve to 18% to 24%. Currently, the standard therapy for pancreatic cancer is gemcitabine, alone or in combination with other chemotherapeutics.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or ``naked'' form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have exclusively licensed our lead product candidate, epratuzumab, to UCB (http://www.ucb-group.com) for the treatment of all autoimmune disease indications worldwide. Epratuzumab's most advanced program is for the treatment of systemic lupus erythematosus (SLE). At present, there is no cure for lupus and no new lupus drug has been approved in the U.S. in the last 40 years. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. The Company is conducting clinical trials with veltuzumab in patients with non-Hodgkin's lymphoma, epratuzumab as a potential therapeutic for patients with lymphoma and leukemia, 90Y-epratuzumab for the therapy of patients with lymphoma, 90Y-hPAM4 for pancreas cancer therapy and milatuzumab as a therapy for patients with multiple myeloma. We believe that our portfolio of intellectual property, which includes approximately 108 patents issued in the United States, and more than 250 other issued patents worldwide, protects our product candidates and technologies. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. For additional information on us, please visit our web site at http://www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partner for the further development of epratuzumab for autoimmune indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
          Immunomedics, Inc.
          Dr. Chau Cheng, Associate Director,
           Investor Relations & Business Analysis
          (973) 605-8200, extension 123
          [email protected]


--------------------------------------------------------------------------------
Source: Immunomedics, Inc.

[setravis]

Popped today ... (Long Recommendation).......follow through after increase in accumulation !
Terrific move today, foreboding move may indicate further improvement as biotechs are warming up !!


52wk Range: 1.92 - 6.12
Volume: 2,938,876
Avg Vol (3m): 891,097

Technicals
Close Above the 50-day MA
Most Actives
Percentage Gainer

Last Price Quote is:
29.06%above 13-day MA
18.02%above 50-day MA
RS Rating: 6 

Fundamentals
Key Data:
Market Cap (M): $172.64 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/05/2007
Last Analyst Rating: Buy